» Articles » PMID: 26342798

Bone Marrow-derived Mesenchymal Stem Cells Suppress NK Cell Recruitment and Activation in PolyI:C-induced Liver Injury

Overview
Publisher Elsevier
Specialty Biochemistry
Date 2015 Sep 7
PMID 26342798
Citations 17
Authors
Affiliations
Soon will be listed here.
Abstract

Mesenchymal stem cells (MSCs) have been shown to have an immunomodulatory capability and clinical potential in immune diseases. However, it is unknown how MSCs may affect immunity in liver injury. This study was designed to explore the effect of bone marrow-derived MSCs (BM-MSCs) on hepatic natural killer (NK) cells in polyinosinic-polycytidylic acid (PolyI:C)-induced liver injury. Unlike in controls, adoptive transfer of BM-MSCs in mice ameliorated PolyI:C-induced liver injury, as shown by lower alanine aminotransferase levels and decreased lymphocyte infiltration in the liver. Importantly, BM-MSCs suppress NK cell accumulation and activation in the liver, which plays an important role in PolyI:C-induced liver injury. Furthermore, NK cells co-cultured with BM-MSCs reduced expression of sphingosine-1-phosphate receptor type 5 (S1PR5), an important receptor required for NK cell trafficking in vivo. BM-MSC administration suppressed the elevation of expression of S1PR5 in the liver induced by PolyI:C injection. Accordingly, BM-MSCs inhibited the chemotactic activity of NK cells induced by sphingosine-1-phosphate (S1P, the ligand of S1PR5). Our results provide an additional mechanism for the immunosuppressive effect of BM-MSCs on NK cells, which further supports the therapeutic potential of BM-MSCs in immune-mediated disorders, including those in which NK cells play a major role.

Citing Articles

Regulatory role of S1P and its receptors in sepsis-induced liver injury.

Wang B, Wu X, Cheng J, Ye J, Zhu H, Liu X Front Immunol. 2025; 16:1489015.

PMID: 39935473 PMC: 11811114. DOI: 10.3389/fimmu.2025.1489015.


Fate and long-lasting therapeutic effects of mesenchymal stromal/stem-like cells: mechanistic insights.

Hoseinzadeh A, Esmaeili S, Sahebi R, Melak A, Mahmoudi M, Hasannia M Stem Cell Res Ther. 2025; 16(1):33.

PMID: 39901306 PMC: 11792531. DOI: 10.1186/s13287-025-04158-z.


Exosomes derived from microRNA-540-3p overexpressing mesenchymal stem cells promote immune tolerance the CD74/nuclear factor-kappaB pathway in cardiac allograft.

He J, Wu X, Li S, Yan D, Xiao G, Mao F World J Stem Cells. 2024; 16(12):1022-1046.

PMID: 39734479 PMC: 11669987. DOI: 10.4252/wjsc.v16.i12.1022.


Mesenchymal stem cell therapy for liver transplantation: clinical progress and immunomodulatory properties.

Wen F, Yang G, Yu S, Liu H, Liao N, Liu Z Stem Cell Res Ther. 2024; 15(1):320.

PMID: 39334441 PMC: 11438256. DOI: 10.1186/s13287-024-03943-6.


Potential mesenchymal stem cell therapeutics for treating primary biliary cholangitis: advances, challenges, and perspectives.

Yang Y, Zhao R, Zhang F Front Cell Dev Biol. 2022; 10:933565.

PMID: 35923849 PMC: 9339990. DOI: 10.3389/fcell.2022.933565.